Table 1 Patients and controls included in this study
From: Red blood cell-derived arginase release in hemolytic uremic syndrome
Subjects | n | Age years, median (range) | M/F | Sample | Analysis |
|---|---|---|---|---|---|
HUS cohort (Lund) | 24 | 2.5 (0.25–14) | 16/8 | Plasma | Arginase 1 levels and activity, A1M |
Controls to HUS cohort (Lund) |  8 | 10 (1–15) | 5/3 | Plasma | Arginase 1 levels and activity, A1M |
HUS cohort (Philadelphia) | 23 | 3 (0.5–14) | 11/12 | Serum | Arginase 1 levels |
Controls to HUS cohort (Philadelphia) | 26 | 8.5 (6–15) | 16/10 | Serum | Arginase 1 levels |
TTP patients |  3 | 9 (7–21) | 2/1 | Plasma | In vitro TMA model |
Healthy controls | Â 4 | Adults | 3/1 | Whole blood, Plasma | In vitro TMA model, RBC lysate-Arginase 1 level |